GRCL
Gracell Biotechnologies Inc.
485.20$
-2.8%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 86.2% | 82.6% | 84.5% | 91.5% | 90.3% | |
| 8.0% | 75.7% | 78.2% | 88.8% | 87.8% | |
| 76.7% | 76.7% | 80.1% | 89.0% | 88.0% | |
| 4.2% | 3.3% | 3.2% | 2.0% | 1.6% | |
| 5.2% | 2.3% | -3.2% | 0.4% | -1.6% | |
| 11.0% | 11.7% | 12.3% | 7.4% | 8.7% | |
| 98.4% | 38.1% | 15.1% | 11.3% | 16.9% | |
| 5.0% | 4.4% | 9.7% | 7.5% | 13.3% | |
| – | – | 5.3% | 4.2% | 7.8% | |
| – | – | – | 3.0% | – | |
| 93.4% | 33.6% | 5.4% | 2.6% | 2.8% | |
| 1.6% | 61.9% | 84.9% | 88.7% | 83.1% | |
| -54.6% | -70.2% | -58.5% | -49.4% | -98.1% | |
| 2.7% | 1.0% | 1.4% | 0.6% | 0.8% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.